Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Early Combination Of Enbrel(R) (etanercept) And Methotrexate Halts Radiographic Progression In 90% Of Patients During Second Year Of The COMET Study
New data presented this week during the European League Against Rheumatism (EULAR) Annual Meeting in Copenhagen demonstrated that sustained combination therapy (etanercept and methotrexate) was consistently superior to continuous methotrexate monotherapy in providing clinical remission and radiographic non-progression over two years in patients with early active rheumatoid arthritis.1 These new data add to the body of evidence supporting the benefits of early intervention with a biologic treatment in patients with rheumatoid arthritis.
generic viagra online
14.3 Million Midwives, Nurses And Doctors Demand Action On Maternal Deaths At July G8 Summit
In an unprecedented move today, millions of midwives, nurses and doctors across the world delivered a message to G8 leaders to take urgent action to prevent women dying needlessly in pregnancy and childbirth.
News of the day
BMA Scotland GP Leader Calls On Scottish Government To Listen, Support And Work With GPs To Help Improve Patient Care
As GPs across the UK gathered in London for the Annual Conference of Local Medical Committees, Dr Dean Marshall, chairman of the BMA"s Scottish General Practitioners Committee, slammed the government for trying to strip GPs of funding and called for the profession to make decisions about general practice, not civil servants.
Diagnostics

Endeavor Drug-Eluting Stent Is First To Receive CE Mark For Treating Acute Coronary Syndrome

Medtronic, Inc. (NYSE: MDT), announced that its Endeavor drug-eluting stent (DES) is the first and only coronary stent to have received CE (Conformité Européene) Mark approval for treating patients with acute coronary syndrome (ACS), which includes unstable angina and acute myocardial infarction (AMI), commonly known as heart attack. Medtronic is launching the unique ACS indication for the Endeavor DES today at PCR, a large and prestigious international meeting of interventional cardiologists. At this meeting today, Prof. Martin Rothman of the London Chest Hospital in the U.K. released positive new 12Ò€òmonth data from the international realÒ€òworld registry EÒ€òFive study (n=8,314) that show comparable outcomes for Endeavor DES patients with and without ACS . "Considering the distinctive safety record of the Endeavor stent, this indication for ACS makes perfect sense," said Prof. Rothman. "Results from the EÒ€òFive study support the use of the Endeavor stent in realÒ€òworld clinical practice, including ACS patients." Clinical research shows that ACS patients are at higher risk of stent thrombosis and mortality than nonÒ€òACS patients. ACS is a complex disease state for which drugÒ€òeluting stents are sometimes avoided due to concerns over longÒ€òterm safety and patient compliance with antiplatelet medication. "Of critical importance for safety, the biocompatibility of the Endeavor stent allows rapid and complete healing of the vessel wall," explained Sean Salmon, vice president and general manager of Medtronic CardioVascular"s Coronary and Peripheral business. "We believe that this healthy healing is the key to longÒ€òterm safety and efficacy." The EÒ€òFive study demonstrated no statistically significant difference on the primary endpoint - the rate of major adverse cardiac events (MACE) at one year - between ACS patients (7.8 percent, n=3,973) and nonÒ€òACS patients (7.2 percent, n=4,341). Rates of death, MI and late stent thrombosis (LST) at one year were similarly low and comparable between the two groups. - AllÒ€òcause mortality - 2.7% ACS, 2.2%, nonÒ€òACS - Cardiac death - 2.0% ACS, 1.5% nonÒ€òACS - MI - 1.8% ACS, 1.5% nonÒ€òACS - Cardiac death + MI - 3.4% ACS, 2.7% nonÒ€òACS - LST (ARC def/prob) - 0.5% ACS, 0.3% nonÒ€òACS Low and similar rates of standard efficacy measures were also observed, including target lesion revascularization (TLR), target vessel revascularization (TVR) and target vessel failure (TVF). On all these measures, there were no statistically significant differences between the ACS and nonÒ€òACS groups. Medtronic"s Endeavor stent originally received the CE mark in August 2005 as a treatment for coronary artery disease. This latest approval enables Medtronic to market the Endeavor DES specifically for ACS patients in the European Union, and all other countries that recognize the CE Mark. These countries do not include the United States or Japan, where the Endeavor DES is also commercially available but is not indicated for ACS patients. Medtronic, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009